Lorcaserin Designated as a Schedule IV Controlled Substance


Back Arrow

Back To The Calendar


Topic Lorcaserin Designated as a Schedule IV Controlled Substance
Background The Administrator of the Drug Enforcement Administration (DEA) placed the substance Lorcaserin, including its salts, isomers and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible, into Schedule IV of the United States Controlled Substances Act (USCSA) effective June 7, 2013. This final rule was published in the Federal Register. The Administrator of the DEA has taken this action based on the following: (1) Lorcaserin has a low potential for abuse relative to the drugs or other substances in Schedule III. (2) Lorcaserin has a currently accepted medical use in treatment in the United States. (3) Abuse of Lorcaserin may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in Schedule III. Schedule IV other substances Unless specifically excepted or unless listed in another schedule, a material, compound, or preparation containing the following substances or their salts: (1) Butorphanol, including its optical isomers; (2) Carisoprodol; (3)* Lorcaserin including its salts, isomers and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible; (4) Pentazocine, its salts, derivatives, compounds, or mixtures.
Regulating Body Texas Department of State Health Services
Compliance Date 8/15/2013
Consequences A prescription for a Schedule IV drug, which now includes Lorcaserin, may not be filled or refilled later than six months after the date the prescription is issued and may not be refilled more than five times, unless the prescription is renewed by the physician.
Next Steps Be aware of the refill limitation for Lorcaserin.
Find out how TMA can help!